Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sindilimab plus nab-paclitaxel as second-line treatment for advanced or metastatic urothelial carcinoma
ChiCTR2100045774Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and paclitaxel in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression-free survival. Started Sep 2019; status: recruiting.
02
Drugs
sintilimabpaclitaxel
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on ChiCTR2100045774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045774.